查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
Bcma 針對治療市場，按類型、癌症、最終用戶、國家和地區 - 2024-2032 年行業分析、市場規模、市場佔有率和預測
市場調查報告書
商品編碼
1419021

Bcma 針對治療市場，按類型、癌症、最終用戶、國家和地區 - 2024-2032 年行業分析、市場規模、市場佔有率和預測

Bcma Targeted Therapies Market, By Type, By Cancer, By End-User, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032
出版日期: | 出版商: AnalystView Market Insights | 英文 299 Pages | 商品交期: 2-3個工作天內

價格

報告要點

2023 年 Bcma 標靶治療市場規模為 90.1 億美元，2024 年至 2032 年CAGR為 20.5%。

Bcma 標靶治療市場-市場動態

多發性骨髓瘤復發病例數量的增加預計將推動 B 細胞成熟抗原 (BCMA) 標靶治療市場的成長

BCMA標靶治療，例如標靶治療，透過專門關注表達BCMA的癌細胞，提供了更精確的方法。這種方法有可能帶來更有效、危害較小的治療方法，從而解決未滿足的醫療需求。據美國臨床腫瘤學會稱，到 2023 年，美國估計將有 35,730 名成年人（19,860 名男性和 15,870 名女性）被診斷出患有多發性骨髓瘤。 2020 年，全球估計有176,404 人被診斷出患有多發性骨髓瘤。此外，在理解多發性骨髓瘤的分子和遺傳基礎方面不斷取得的進展可能會導致新治療靶點的確定和更有效的BCMA標靶療法的開發。然而，值得注意的是，這些療法的高成本可能會阻礙市場成長。

Bcma 標靶治療市場 - 關鍵見解

  • 根據我們的研究分析師分享的分析，預計全球 Bcma 標靶治療市場在預測期內（2024-2032 年）每年將以 20.5% 左右的CAGR成長
  • 根據類型細分，預計嵌合抗原受體 T 細胞將在 2023 年顯示最大的市場佔有率
  • 根據最終用戶細分，醫院是 2023 年的領先類型
  • 按地區分類，北美是 2023 年的主要收入來源

Bcma 標靶治療市場-細分分析：

全球 Bcma 標靶治療市場根據類型、癌症、最終用戶和地區進行細分。

市場根據類型分為三類：雙特異性抗體、抗體藥物偶聯物和嵌合抗原受體 T 細胞。此市場主要由嵌合抗原受體 T 細胞領域主導。多發性骨髓瘤細胞是一種影響漿細胞的癌症，在其表面表達一種稱為 BCMA 的蛋白質。 CAR-T細胞療法是一種免疫療法，涉及修改患者自身的T細胞以表達能夠識別和攻擊癌細胞的嵌合抗原受體（CAR）。

根據癌症類型，市場分為三類：肝癌、呼吸道癌、腦癌和其他癌症。 B 細胞成熟抗原 (BCMA) 標靶療法主要用於治療多發性骨髓瘤，這是一種影響漿細胞的癌症。 BCMA 存在於多發性骨髓瘤細胞的表面，這使其成為治療介入的主要目標。

根據最終用戶，市場分為兩類：醫院和癌症研究所。市場主要由醫院部門控制。為了改善患者護理和支援服務，醫院可能必須專注於管理 BCMA 標靶治療的潛在副作用，並為接受治療的患者提供全面護理。對於醫院來說，遵守癌症治療管理的監管要求、確保方案符合衛生當局製定的安全性和有效性標準至關重要。

Bcma 標靶治療市場 - 地理洞察

從地理來看，該市場遍佈北美、拉丁美洲、歐洲、亞太、中東和非洲等多個地區。這些區域根據參與商業活動的國家進一步分類。預計該市場的成長將由北美主導，這主要是由於對多發性骨髓瘤創新療法的研發投資不斷增加。美國是臨床研究的主要中心，對包括多發性骨髓瘤在內的各種疾病進行了大量的臨床試驗。著名研究機構、學術醫療中心和生物技術公司的存在為臨床試驗提供了強大的基礎設施，從而促進了新療法的開發。根據國家衛生支出數據，美國醫療衛生研發投入大幅成長，2020年達到2451億美元，較2019年成長11.1%。- 私部門研發系統在2020 年發生了變化，可能受到對COVID-19 大流行的反應和影響的影響。

Bcma 標靶治療市場-競爭格局：

BCMA 標靶療法市場的特點是競爭格局動態，許多製藥和生物技術公司積極參與這些療法的開發。這些療法已證明在治療多發性骨髓瘤方面具有臨床有效性，特別是對於復發或對其他治療方案表現出抗藥性的患者。許多公司目前都參與開發 BCMA 標靶療法的臨床前和臨床階段，無論是作為獨立療法還是與其他藥物合併使用。例如，2023年1月31日，專門從事細胞和基因治療的臨床階段公司Poseida Therapeutics, Inc.宣布Eric Ostertag博士辭去執行主席職務並退休董事會任命，於2023 年2 月3 日生效。不過，Ostertag 博士將繼續作為顧問為公司做出貢獻，提供技術和科學事務的寶貴專業知識。

最近的發展：

2022 年 11 月 17 日，預計到 2040 年，全球將出現超過 275,000 例多發性骨髓瘤新病例。多發性骨髓瘤是一种血癌，其特徵是通常起源於骨髓的惡性漿細胞增殖。 B 細胞成熟抗原 (BCMA) 是一種重要的細胞表面抗原，幾乎存在於所有多發性骨髓瘤病例中，但在漿細胞以外的正常組織中表達有限。這使其成為多發性骨髓瘤治療的關鍵標靶。

目錄

第 1 章：Bcma 標靶治療市場概述

  • 研究範圍
  • 市場預估年份

第 2 章：執行摘要

  • 市場片段
    • Bcma 標靶治療市場片段（按類型）
    • Bcma 癌症標靶治療市場片段
    • Bcma 標靶治療市場片段（按最終用戶）
    • Bcma 標靶治療市場片段（按國家/地區）
    • Bcma 標靶治療市場片段（按地區）
  • 競爭洞察

第 3 章：Bcma 標靶治療主要市場趨勢

  • Bcma 標靶治療市場促進因素
    • 市場促進因素的影響分析
  • Bcma 標靶治療市場限制
    • 市場限制影響分析
  • Bcma 標靶治療市場機會
  • Bcma標靶治療市場未來趨勢

第 4 章：Bcma 標靶治療產業研究

  • PEST分析
  • 波特五力分析
  • 成長前景圖
  • 規範架構分析

第 5 章：Bcma 標靶治療市場：COVID-19 影響分析

  • COVID-19 之前的影響分析
  • COVID-19 後影響分析
    • 表現最佳的市場區隔
    • 邊際成長市場區隔
    • 最寬鬆的市場區隔
    • 邊際損失市場區隔

第 6 章：Bcma 標靶治療市場格局

  • Bcma 標靶治療市場佔有率分析，2023 年
  • 按主要製造商分類的故障數據
    • 既有參與者分析
    • 新興參與者分析

第 7 章：Bcma 標靶治療市場 - 按類型

  • 概述
    • 按類型分類的細分市場佔有率分析
    • 雙特異性抗體
    • 抗體藥物偶聯物
    • 嵌合抗原受體 T 細胞

第 8 章：Bcma 標靶治療市場 - 按癌症分類

  • 概述
    • 按癌症分類的細分市場佔有率分析
    • 肝癌
    • 呼吸道癌
    • 腦癌
    • 其他

第 9 章：Bcma 標靶治療市場 - 按最終用戶

  • 概述
    • 按最終用戶分類的細分市場佔有率分析
    • 醫院
    • 癌症研究所

第 10 章：Bcma 標靶治療市場 - 按地理位置

  • 介紹
    • 按地理位置分類的細分市場佔有率分析
  • 北美洲
    • 概述
    • Bcma 標靶治療北美主要製造商
    • 北美市場規模和預測（按國家）
    • 北美市場規模和預測（按類型）
    • 北美市場規模與預測（按癌症）
    • 北美市場規模和預測（按最終用戶）
    • 美國
    • 加拿大
  • 歐洲
    • 概述
    • Bcma 標靶治療歐洲主要製造商
    • 歐洲市場規模和預測（按國家）
    • 歐洲市場規模與預測（按類型）
    • 歐洲市場規模與預測（按癌症）
    • 歐洲市場規模和預測（按最終用戶）
    • 德國
    • 義大利
    • 英國
    • 法國
    • 俄羅斯
    • 荷蘭
    • 瑞典
    • 波蘭
    • 歐洲其他地區
  • 亞太地區 (APAC)
    • 概述
    • Bcma 標靶治療亞太地區主要製造商
    • 亞太地區市場規模與預測（按國家）
    • 亞太地區市場規模與預測（按類型）
    • 亞太地區癌症市場規模與預測
    • 亞太地區市場規模和預測（按最終用戶）
    • 印度
    • 中國
    • 日本
    • 韓國
    • 澳洲
    • 泰國
    • 印尼
    • 菲律賓
    • 亞太地區其他地區
  • 拉丁美洲
    • 概述
    • Bcma 標靶治療拉丁美洲主要製造商
    • 拉丁美洲市場規模與預測（按國家）
    • 拉丁美洲市場規模與預測（按類型）
    • 拉丁美洲市場規模與預測（按癌症）
    • 拉丁美洲市場規模和預測（按最終用戶）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥倫比亞
    • 拉丁美洲其他地區
  • 中東和非洲
    • 概述
    • Bcma 標靶治療中東和非洲主要製造商
    • 中東和非洲市場規模及預測（按國家）
    • 中東和非洲市場規模及預測（按類型）
    • 中東和非洲市場規模及預測（按癌症）
    • 中東和非洲市場規模和預測（按最終用戶）
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 以色列
    • 土耳其
    • 阿爾及利亞
    • 埃及
    • MEA 的其餘部分

第 11 章：主要供應商分析 - Bcma 標靶治療產業

  • 競爭儀表板
  • 公司簡介
    • Transposagen Biopharmaceuticals
    • Sutro Biopharma
    • Malin Corporation
    • Eureka Therapeutics
    • firstVentury Equity
    • Five Prime Therapeutics
    • Credit Suisse Securities
    • Dana-Farber Cancer Institute
    • Deerfield Partners
    • Onyx Pharmaceuticals
    • Juno Therapeutics

第 12 章：360 度分析師視角

第 13 章：附錄

  • 研究方法論
  • 參考
  • 縮寫
  • 免責聲明
  • 聯絡我們
Product Code: ANV2086

REPORT HIGHLIGHT

Bcma Targeted Therapies Market size was valued at USD 9,010 Million in 2023, expanding at a CAGR of 20.5% from 2024 to 2032.

BCMA, or B cell maturation antigen, has emerged as a promising treatment target for multiple myeloma (MM) due to its highly specific expression in malignant plasma cells (PCs). Various BCMA-targeted therapies, such as antibody-drug conjugates (ADC), chimeric antigen receptor (CAR)-T cells, and bispecific T cell engagers (BiTE), have shown remarkable clinical responses in patients with relapsed and refractory MM. The introduction of novel therapeutics like proteasome inhibitors (PI) and immunomodulatory drugs (IMiD) has further enhanced the treatment outcomes for patients with MM. It is estimated that there will be over 275,000 new cases of multiple myeloma worldwide by 2040. Multiple myeloma is a type of blood cancer characterized by the abnormal proliferation of malignant plasma cells, primarily originating in the bone marrow. BCMA, a cell surface antigen predominantly found in multiple myeloma cases, presents a valuable target for therapeutic interventions in this disease.

Bcma Targeted Therapies Market- Market Dynamics

Increasing number of recurring cases of multiple myeloma is expected to drive growth of the B-cell maturation Antigen (BCMA) targeted therapies market

BCMA-targeted therapies, such as targeted treatments, provide a more precise method by specifically focusing on cancer cells that express BCMA. This approach has the potential to result in treatments that are more effective and less harmful, thereby addressing the unmet medical requirements. According to the American Society of Clinical Oncology, In 2023, an estimated 35,730 adults (19,860 men and 15,870 women) in the United States will be diagnosed with multiple myeloma. Worldwide, an estimated 176,404 people were diagnosed with multiple myeloma in 2020. Additionally, ongoing advancements in comprehending the molecular and genetic foundations of multiple myeloma may lead to the identification of new therapeutic targets and the development of more potent BCMA-targeted therapies. However, it is important to note that the high cost of these therapies may hinder market growth.

Bcma Targeted Therapies Market- Key Insights

  • As per the analysis shared by our research analyst, the global Bcma Targeted Therapies market is estimated to grow annually at a CAGR of around 20.5% over the forecast period (2024-2032)
  • Based on Type segmentation, Chimeric Antigen Receptor T-Cells was predicted to show maximum market share in the year 2023
  • Based on End-User segmentation, Hospitals was the leading type in 2023
  • On the basis of region, North America was the leading revenue generator in 2023

Bcma Targeted Therapies Market- Segmentation Analysis:

The Global Bcma Targeted Therapies Market is segmented on the basis of Type, Cancer, End-User, and Region.

The market is divided into three categories based on Type: Bispecific Antibodies, Antibody Drug Conjugates and Chimeric Antigen Receptor T-Cells.The market is largely dominated by the segment of Chimeric Antigen Receptor T-Cells. Multiple myeloma cells, which are a type of cancer that affects plasma cells, express a protein called BCMA on their surface. CAR-T cell therapy is an immunotherapy approach that involves modifying the patient's own T cells to express a chimeric antigen receptor (CAR) capable of identifying and attacking cancer cells.

The market is segmented into three groups according to the type of cancer: Liver Cancer, Respiratory Cancer, Brain Cancer, and Others. B-Cell Maturation Antigen (BCMA) targeted therapies have mainly been used in the treatment of multiple myeloma, a form of cancer that impacts plasma cells. BCMA is present on the surface of multiple myeloma cells, which makes it a prime target for therapeutic interventions.

The market is divided into two categories based on End-User: Hospitals and Cancer Research Institute. The market is largely controlled by the hospitals sector. In order to improve patient care and support services, hospitals may have to focus on managing the potential side effects of BCMA-targeted therapies and providing comprehensive care for patients receiving treatment. It is crucial for hospitals to comply with regulatory requirements for the administration of cancer treatments, ensuring that protocols are in line with the safety and efficacy standards set by health authorities.

Bcma Targeted Therapies Market- Geographical Insights

Geographically, this market is spread across various regions including North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided based on the countries involved in business activities. The growth of the market is expected to be dominated by North America, primarily due to the increasing investments in research and development of innovative therapies for multiple myeloma. The United States serves as a major center for clinical research, hosting numerous clinical trials for various diseases, including multiple myeloma. The presence of renowned research institutions, academic medical centers, and biotechnology companies contributes to a strong infrastructure for conducting clinical trials, thereby facilitating the development of new therapies. According to the National Health Expenditures, the United States (U.S.) witnessed a significant increase in medical and health research and development (R&D) investment, reaching USD 245.1 billion in 2020, marking an 11.1% rise from 2019. The growth rates in the public-private sector R&D ecosystem underwent changes in 2020, likely influenced by the response to and impact of the COVID-19 pandemic.

Bcma Targeted Therapies Market- Competitive Landscape:

The BCMA-targeted therapies market is characterized by a dynamic competitive landscape, with numerous pharmaceutical and biotechnology companies actively engaged in the development of these treatments. These therapies have demonstrated clinical effectiveness in addressing multiple myeloma, particularly in patients who have relapsed or shown resistance to other treatment options. Many companies are currently involved in both preclinical and clinical stages of developing BCMA-targeted therapies, either as standalone treatments or in combination with other drugs. As an example, on January 31, 2023, Poseida Therapeutics, Inc., a clinical-stage company specializing in cell and gene therapy, announced the resignation of Dr. Eric Ostertag, M.D., Ph.D., as Executive Chairman and his retirement from the Board of Directors, effective February 3, 2023. However, Dr. Ostertag will continue to contribute to the company as a consultant, providing valuable expertise in technical and scientific matters.

Recent Developments:

November 17, 2022, More than 275,000 new cases of multiple myeloma are expected to occur globally by the year 2040. Multiple myeloma is a blood cancer characterized by the proliferation of malignant plasma cells that typically originate in the bone marrow. B-cell maturation antigen (BCMA) is an important cell surface antigen found in nearly all cases of multiple myeloma, but with limited expression on normal tissues other than plasma cells. This makes it a key target for multiple myeloma therapeutics.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL BCMA TARGETED THERAPIES MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Transposagen Biopharmaceuticals
  • Sutro Biopharma
  • Malin Corporation
  • Eureka Therapeutics
  • firstVentury Equity
  • Five Prime Therapeutics
  • Credit Suisse Securities
  • Dana-Farber Cancer Institute
  • Deerfield Partners
  • Onyx Pharmaceuticals
  • Juno Therapeutics

GLOBAL BCMA TARGETED THERAPIES MARKET, BY TYPE- MARKET ANALYSIS, 2019 - 2032

  • Bispecific Antibodies
  • Antibody Drug Conjugates
  • Chimeric Antigen Receptor T-Cells

GLOBAL BCMA TARGETED THERAPIES MARKET, BY CANCER- MARKET ANALYSIS, 2019 - 2032

  • Liver Cancer
  • Respiratory Cancer
  • Brain Cancer
  • Others

GLOBAL BCMA TARGETED THERAPIES MARKET, BY END-USER- MARKET ANALYSIS, 2019 - 2032

  • Hospitals
  • Cancer Research Institute

GLOBAL BCMA TARGETED THERAPIES MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Bcma Targeted Therapies Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Bcma Targeted Therapies Market Snippet by Type
    • 2.1.2. Bcma Targeted Therapies Market Snippet by Cancer
    • 2.1.3. Bcma Targeted Therapies Market Snippet by End-User
    • 2.1.4. Bcma Targeted Therapies Market Snippet by Country
    • 2.1.5. Bcma Targeted Therapies Market Snippet by Region
  • 2.2. Competitive Insights

3. Bcma Targeted Therapies Key Market Trends

  • 3.1. Bcma Targeted Therapies Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Bcma Targeted Therapies Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Bcma Targeted Therapies Market Opportunities
  • 3.4. Bcma Targeted Therapies Market Future Trends

4. Bcma Targeted Therapies Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Bcma Targeted Therapies Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Bcma Targeted Therapies Market Landscape

  • 6.1. Bcma Targeted Therapies Market Share Analysis, 2023
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Bcma Targeted Therapies Market - By Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Type, 2023 & 2032 (%)
    • 7.1.2. Bispecific Antibodies
    • 7.1.3. Antibody Drug Conjugates
    • 7.1.4. Chimeric Antigen Receptor T-Cells

8. Bcma Targeted Therapies Market - By Cancer

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Cancer, 2023 & 2032 (%)
    • 8.1.2. Liver Cancer
    • 8.1.3. Respiratory Cancer
    • 8.1.4. Brain Cancer
    • 8.1.5. Others

9. Bcma Targeted Therapies Market - By End-User

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By End-User, 2023 & 2032 (%)
    • 9.1.2. Hospitals
    • 9.1.3. Cancer Research Institute

10. Bcma Targeted Therapies Market- By Geography

  • 10.1. Introduction
    • 10.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
  • 10.2. North America
    • 10.2.1. Overview
    • 10.2.2. Bcma Targeted Therapies Key Manufacturers in North America
    • 10.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.2.4. North America Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.2.5. North America Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
    • 10.2.6. North America Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.2.7. U.S.
      • 10.2.7.1. Overview
      • 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.7.3. U.S. Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.2.7.4. U.S. Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
      • 10.2.7.5. U.S. Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.2.8. Canada
      • 10.2.8.1. Overview
      • 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.8.3. Canada Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.2.8.4. Canada Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
      • 10.2.8.5. Canada Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 10.3. Europe
    • 10.3.1. Overview
    • 10.3.2. Bcma Targeted Therapies Key Manufacturers in Europe
    • 10.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.3.4. Europe Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.3.5. Europe Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
    • 10.3.6. Europe Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.3.7. Germany
      • 10.3.7.1. Overview
      • 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.7.3. Germany Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.7.4. Germany Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
      • 10.3.7.5. Germany Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.3.8. Italy
      • 10.3.8.1. Overview
      • 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.8.3. Italy Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.8.4. Italy Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
      • 10.3.8.5. Italy Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.3.9. United Kingdom
      • 10.3.9.1. Overview
      • 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.9.3. United Kingdom Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.9.4. United Kingdom Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
      • 10.3.9.5. United Kingdom Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.3.10. France
      • 10.3.10.1. Overview
      • 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.10.3. France Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.10.4. France Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
      • 10.3.10.5. France Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.3.11. Russia
      • 10.3.11.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.11.2. Russia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.11.3. Russia Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
      • 10.3.11.4. Russia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.3.12. Netherlands
      • 10.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.12.2. Netherlands Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.12.3. Netherlands Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
      • 10.3.12.4. Netherlands Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.3.13. Sweden
      • 10.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.13.2. Sweden Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.13.3. Sweden Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
      • 10.3.13.4. Sweden Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.3.14. Poland
      • 10.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.14.2. Poland Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.14.3. Poland Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
      • 10.3.14.4. Poland Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.3.15. Rest of Europe
      • 10.3.15.1. Overview
      • 10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.15.3. Rest of the Europe Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.15.4. Rest of the Europe Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
      • 10.3.15.5. Rest of the Europe Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 10.4. Asia Pacific (APAC)
    • 10.4.1. Overview
    • 10.4.2. Bcma Targeted Therapies Key Manufacturers in Asia Pacific
    • 10.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.4.4. Asia Pacific Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.4.5. Asia Pacific Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
    • 10.4.6. Asia Pacific Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.4.7. India
      • 10.4.7.1. Overview
      • 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.7.3. India Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.7.4. India Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
      • 10.4.7.5. India Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.4.8. China
      • 10.4.8.1. Overview
      • 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.8.3. China Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.8.4. China Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
      • 10.4.8.5. China Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.4.9. Japan
      • 10.4.9.1. Overview
      • 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.9.3. Japan Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.9.4. Japan Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
      • 10.4.9.5. Japan Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.4.10. South Korea
      • 10.4.10.1. Overview
      • 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.10.3. South Korea Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.10.4. South Korea Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
      • 10.4.10.5. South Korea Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.4.11. Australia
      • 10.4.11.1. Overview
      • 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.11.3. Australia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.11.4. Australia Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
      • 10.4.11.5. Australia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.4.12. Thailand
      • 10.4.12.1. Overview
      • 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.12.3. Thailand Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.12.4. Thailand Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
      • 10.4.12.5. Thailand Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.4.13. Indonesia
      • 10.4.13.1. Overview
      • 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.13.3. Indonesia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.13.4. Indonesia Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
      • 10.4.13.5. Indonesia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.4.14. Philippines
      • 10.4.14.1. Overview
      • 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.14.3. Philippines Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.14.4. Philippines Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
      • 10.4.14.5. Philippines Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.4.15. Rest of APAC
      • 10.4.15.1. Overview
      • 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.15.3. Rest of APAC Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.15.4. Rest of APAC Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
      • 10.4.15.5. Rest of APAC Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 10.5. Latin America
    • 10.5.1. Overview
    • 10.5.2. Bcma Targeted Therapies Key Manufacturers in Latin America
    • 10.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.5.4. Latin America Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.5.5. Latin America Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
    • 10.5.6. Latin America Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.5.7. Brazil
      • 10.5.7.1. Overview
      • 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.7.3. Brazil Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.5.7.4. Brazil Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
      • 10.5.7.5. Brazil Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.5.8. Mexico
      • 10.5.8.1. Overview
      • 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.8.3. Mexico Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.5.8.4. Mexico Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
      • 10.5.8.5. Mexico Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.5.9. Argentina
      • 10.5.9.1. Overview
      • 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.9.3. Argentina Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.5.9.4. Argentina Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
      • 10.5.9.5. Argentina Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.5.10. Colombia
      • 10.5.10.1. Overview
      • 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.10.3. Colombia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.5.10.4. Colombia Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
      • 10.5.10.5. Colombia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.5.11. Rest of LATAM
      • 10.5.11.1. Overview
      • 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.11.3. Rest of LATAM Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.5.11.4. Rest of LATAM Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
      • 10.5.11.5. Rest of LATAM Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 10.6. Middle East and Africa
    • 10.6.1. Overview
    • 10.6.2. Bcma Targeted Therapies Key Manufacturers in Middle East and Africa
    • 10.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.6.4. Middle East and Africa Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.6.5. Middle East and Africa Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
    • 10.6.6. Middle East and Africa Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.6.7. Saudi Arabia
      • 10.6.7.1. Overview
      • 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.7.3. Saudi Arabia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.7.4. Saudi Arabia Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
      • 10.6.7.5. Saudi Arabia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.6.8. United Arab Emirates
      • 10.6.8.1. Overview
      • 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.8.3. United Arab Emirates Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.8.4. United Arab Emirates Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
      • 10.6.8.5. United Arab Emirates Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.6.9. Israel
      • 10.6.9.1. Overview
      • 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.9.3. Israel Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.9.4. Israel Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
      • 10.6.9.5. Israel Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.6.10. Turkey
      • 10.6.10.1. Overview
      • 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.10.3. Turkey Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.10.4. Turkey Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
      • 10.6.10.5. Turkey Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.6.11. Algeria
      • 10.6.11.1. Overview
      • 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.11.3. Algeria Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.11.4. Algeria Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
      • 10.6.11.5. Algeria Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.6.12. Egypt
      • 10.6.12.1. Overview
      • 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.12.3. Egypt Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.12.4. Egypt Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
      • 10.6.12.5. Egypt Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.6.13. Rest of MEA
      • 10.6.13.1. Overview
      • 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.13.3. Rest of MEA Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.13.4. Rest of MEA Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
      • 10.6.13.5. Rest of MEA Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)

11. Key Vendor Analysis- Bcma Targeted Therapies Industry

  • 11.1. Competitive Dashboard
  • 11.2. Company Profiles
    • 11.2.1. Transposagen Biopharmaceuticals
    • 11.2.2. Sutro Biopharma
    • 11.2.3. Malin Corporation
    • 11.2.4. Eureka Therapeutics
    • 11.2.5. firstVentury Equity
    • 11.2.6. Five Prime Therapeutics
    • 11.2.7. Credit Suisse Securities
    • 11.2.8. Dana-Farber Cancer Institute
    • 11.2.9. Deerfield Partners
    • 11.2.10. Onyx Pharmaceuticals
    • 11.2.11. Juno Therapeutics

12. 360 Degree Analyst View

13. Appendix

  • 13.1. Research Methodology
  • 13.2. References
  • 13.3. Abbreviations
  • 13.4. Disclaimer
  • 13.5. Contact Us

List of Tables

  • TABLE List of data sources
  • TABLE Market drivers; Impact Analysis
  • TABLE Market restraints; Impact Analysis
  • TABLE Bcma Targeted Therapies Market: Type Snapshot (2023)
  • TABLE Segment Dashboard; Definition and Scope, by Type
  • TABLE Global Bcma Targeted Therapies Market, by Type 2019-2032 (USD Million)
  • TABLE Bcma Targeted Therapies Market: Cancer Snapshot (2023)
  • TABLE Segment Dashboard; Definition and Scope, by Cancer
  • TABLE Global Bcma Targeted Therapies Market, by Cancer 2019-2032 (USD Million)
  • TABLE Bcma Targeted Therapies Market: End-User Snapshot (2023)
  • TABLE Segment Dashboard; Definition and Scope, by End-User
  • TABLE Global Bcma Targeted Therapies Market, by End-User 2019-2032 (USD Million)
  • TABLE Bcma Targeted Therapies Market: Regional snapshot (2023)
  • TABLE Segment Dashboard; Definition and Scope, by Region
  • TABLE Global Bcma Targeted Therapies Market, by Region 2019-2032 (USD Million)
  • TABLE North America Bcma Targeted Therapies Market, by Country, 2019-2032 (USD Million)
  • TABLE North America Bcma Targeted Therapies Market, by Type, 2019-2032 (USD Million)
  • TABLE North America Bcma Targeted Therapies Market, by Cancer, 2019-2032 (USD Million)
  • TABLE North America Bcma Targeted Therapies Market, by End-User, 2019-2032 (USD Million)
  • TABLE Europe Bcma Targeted Therapies Market, by Country, 2019-2032 (USD Million)
  • TABLE Europe Bcma Targeted Therapies Market, by Type, 2019-2032 (USD Million)
  • TABLE Europe Bcma Targeted Therapies Market, by Cancer, 2019-2032 (USD Million)
  • TABLE Europe Bcma Targeted Therapies Market, by End-User, 2019-2032 (USD Million)
  • TABLE Asia Pacific Bcma Targeted Therapies Market, by Country, 2019-2032 (USD Million)
  • TABLE Asia Pacific Bcma Targeted Therapies Market, by Type, 2019-2032 (USD Million)
  • TABLE Asia Pacific Bcma Targeted Therapies Market, by Cancer, 2019-2032 (USD Million)
  • TABLE Asia Pacific Bcma Targeted Therapies Market, by End-User, 2019-2032 (USD Million)
  • TABLE Latin America Bcma Targeted Therapies Market, by Country, 2019-2032 (USD Million)
  • TABLE Latin America Bcma Targeted Therapies Market, by Type, 2019-2032 (USD Million)
  • TABLE Latin America Bcma Targeted Therapies Market, by Cancer, 2019-2032 (USD Million)
  • TABLE Latin America Bcma Targeted Therapies Market, by End-User, 2019-2032 (USD Million)
  • TABLE Middle East and Africa Bcma Targeted Therapies Market, by Country, 2019-2032 (USD Million)
  • TABLE Middle East and Africa Bcma Targeted Therapies Market, by Type, 2019-2032 (USD Million)
  • TABLE Middle East and Africa Bcma Targeted Therapies Market, by Cancer, 2019-2032 (USD Million)
  • TABLE Middle East and Africa Bcma Targeted Therapies Market, by End-User, 2019-2032 (USD Million)